{
  "attach_pages": "3",
  "attach_size": "277",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201909261367671528_1.pdf?1569577964000.pdf",
  "company_code": "80000119",
  "eitime": "2019-09-27 09:52:44",
  "extend": {},
  "info_code": "AP201909261367671528",
  "language": "0",
  "notice_date": "2019-09-26 00:00:00",
  "notice_title": "2019H1净利YOY-2.8%，参股公司初期亏损及费用增加拖累短期业绩增速",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "researcher": "王睿哲",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "复星医药",
      "short_name_ch": "复星医药",
      "short_name_cht": "復星醫藥",
      "short_name_en": "FOSUN PHARMA",
      "stock": "600196"
    }
  ],
  "short_name": "复星医药",
  "source_sample_name": "群益证券",
  "star": "1"
}